The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
National Experience on Down‐Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha‐Fetoprotein, and Wait Time
Open accessAbstract
Background and Aims: United Network for Organ Sharing (UNOS) recently implemented a national policy granting priority listing for liver transplantation (LT) in patients who achieved down‐staging of hepatocellular carcinoma (HCC) to Milan criteria. We aimed to evaluate the national experience on down‐staging by comparing two down‐staging groups with (1) tumor burden meeting UNOS down‐staging (UNOS‐DS) inclusion criteria and (2) “all‐comers” (AC‐DS) with initial tumor burden beyond UNOS‐DS criteria versus patients always within Milan. Approach and Results: This is a retrospective analysis of the UNOS database of 3,819 patients who underwent LT from 2012 to 2015, classified as always within Milan (n = 3,276), UNOS‐DS (n = 422), and AC‐DS (n = 121). Median time to LT was 12.8 months in long wait regions, 6.5 months in mid wait regions (MWR), and 2.6 months in short wait regions (SWR). On explant, vascular invasion was found in 23.7% of AC‐DS versus 16.9% of UNOS‐DS and 14.4% of Milan (P = 0.002). Kaplan‐Meier 3‐year post‐LT survival was 83.2% for Milan, 79.1% for UNOS‐DS (P = 0.17 vs. Milan), and 71.4% for AC‐DS (P = 0.04 vs. Milan). Within down‐staging groups, risk of post‐LT death in multivariable analysis was increased in SWR or MWR (hazard ratio [HR], 3.1; P = 0.005) and with alpha‐fetoprotein (AFP) ≥ 100 ng/mL at LT (HR, 2.4; P = 0.009). The 3‐year HCC recurrence probability was 6.9% for Milan, 12.8% for UNOS‐DS, and 16.7% for AC‐DS (P < 0.001). In down‐staging groups, AFP ≥ 100 (HR, 2.6; P = 0.02) was the only independent predictor of HCC recurrence. Conclusions: Our results validated UNOS‐DS criteria based on comparable 3‐year survival between UNOS‐DS and Milan groups. Additional refinements based on AFP and wait time may further improve post‐LT outcomes in down‐staging groups, especially given that reported 3‐year recurrence was higher than in those always within Milan criteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Mazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J., Cescon, M., Di Sandro, S., Yi-feng, H., Lauterio, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.09.025 · Cited by 655
Cited by
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“[238] Therefore, patients in the United States initially exceeding UNOS-DS criteria are considered for MELD exception after successful downstaging on a case-by-case basis by the National Liver Review Board.”
Self-citationEASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, F., Dirchwolf, M., & Pessôa, M. G. (2020) · Cells · doi:10.3390/cells9061370 · Cited by 498
Ganesan, P., & Kulik, L. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.004 · Cited by 478
Metadata
- Authors
- Mehta, N., Dodge, J. L., Grab, J. D., & Yao, F. Y.
- Venue
- Hepatology
- Published
- 2019-10-15
- Volume
- 71
- Issue
- 3
- Pages
- 943-954
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2964249613
- Cited by
- 162
- References
- 2
- FWCI
- 11.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: National Experience on Down‐Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha‐Fetoprotein, and Wait Time. https://app.cochat.ai/papers/10.1002/hep.30879
- The paper
- Mehta, N., Dodge, J. L., Grab, J. D., & Yao, F. Y. (2020). National Experience on Down‐Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha‐Fetoprotein, and Wait Time. Hepatology. https://doi.org/10.1002/hep.30879
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.